NY-MSCI/MICROSOFT
MSCI Inc. (NYSE:MSCI) and Microsoft Corp. have formed a strategic alliance to accelerate innovation among the global investment industry. By bringing together the power of Microsoft’s cloud and AI technologies with MSCI’s global reach through its portfolio of investment decision support tools, the companies will unlock new innovations for the industry and enhance MSCI’s client experience among the world’s most sophisticated investors, including asset managers, asset owners, hedge funds and banks.
Initially, the companies will focus on migrating MSCI’s existing products, data and services onto Azure as its preferred cloud platform in stages, starting with its Index and Analytics solutions followed by its Environmental, Social and Governance (ESG) products and ratings; Real Estate data and solutions; and MSCI’s risk analytics platform Beon . By modernizing MSCI’s data and analytics services and infrastructure, the companies will be able to deliver new capabilities which will help investors more swiftly and efficiently manage data and understand the drivers of risk and performance.
In addition, MSCI and Microsoft will explore collaboration opportunities to drive climate risk and ESG solutions, leveraging Microsoft’s Azure and Power Platform and MSCI’s ESG and climate solutions capabilities. This future collaboration, in line with both organizations’ commitment to sustainability, is intended to help investors better understand and interpret the business risks and opportunities that climate change brings.
“Investors’ needs to rapidly innovate and adapt as strategies and business models evolve, build and manage big data, and improve operational efficiencies are growing at a critical speed around the world,” said Henry Fernandez, Chairman and CEO of MSCI. “Our strategic alliance with Microsoft underscores MSCI’s commitment to driving relentless innovation in the technology of our products and services to help investors achieve their desired investment outcomes.”
“Our strategic collaboration with Microsoft is the latest step in our long and established heritage of innovation and we are excited about the long-term potential of this relationship,” added Jigar Thakkar, Chief Technology Officer and Head of Engineering at MSCI. “MSCI is a future-focused business and Azure enables us not just to enhance our capabilities and client solutions of today, but also provide the platform to accelerate our journey in building world-class technology and tools to solve the investment industry’s challenges of tomorrow.”
“Investors rely on cutting-edge technologies to deliver intelligent insights, manage risk and detect anomalies so they can help customers achieve their investment goals,” said Scott Guthrie, Executive Vice President, Cloud +AI, Microsoft. “By harnessing the power of Azure and its AI capabilities, together with MSCI’s expertise and position within the investment ecosystem, we will be able to accelerate new innovations that help investors better optimize their clients’ performance capabilities.”
“This alliance opens exciting frontiers for the global investment community,” said Merrie Williamson, Microsoft VP of Azure Apps and Infrastructure. “The combination of MSCI’s relentless pursuit of innovation with Microsoft’s deep data expertise, expansive partner ecosystem, and go-to-market capabilities forms an alliance with the potential to accelerate the investment industry.”
About MSCI
MSCI is a leading provider of critical decision support tools and services for the global investment community. With over 45 years of expertise in research, data and technology, we power better investment decisions by enabling clients to understand and analyze key drivers of risk and return and confidently build more effective portfolios. We create industry-leading research-enhanced solutions that clients use to gain insight into and improve transparency across the investment process. To learn more, please visit www.msci.com .
About Microsoft
Microsoft (Nasdaq “MSFT” @microsoft) enables digital transformation for the era of an intelligent cloud and an intelligent edge. Its mission is to empower every person and every organization on the planet to achieve more.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to future events or to future financial performance and involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these statements. In some cases, you can identify forward-looking statements by the use of words such as “may,” “could,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential” or “continue,” or the negative of these terms or other comparable terminology. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond MSCI’s control and that could materially affect actual results, levels of activity, performance or achievements.
Other factors that could materially affect actual results, levels of activity, performance or achievements can be found in MSCI’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 filed with the Securities and Exchange Commission (“SEC”) on February 18, 2020 and in quarterly reports on Form 10-Q and current reports on Form 8-K filed or furnished with the SEC. If any of these risks or uncertainties materialize, or if MSCI’s underlying assumptions prove to be incorrect, actual results may vary significantly from what MSCI projected. Any forward-looking statement in this press release reflects MSCI’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to MSCI’s operations, results of operations, growth strategy and liquidity. MSCI assumes no obligation to publicly update or revise these forward-looking statements for any reason, whether as a result of new information, future events, or otherwise, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200723005265/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Colorectal, Liver, and Lung Cancer Patients at Vinmec Experience Extended Survival with AIET Cell-Based Immunotherapy – Technology Transferred from Japan27.10.2025 07:39:00 CET | Press release
Vinmec Health System attracts international patients to Vietnam for treatment Significantly extended survival and improved quality of life (QoL) for cancer patients achieved through autologous cell-based AIET immunotherapy, utilizing patients' own natural killer (NK) cells and T cells, has positioned Vinmec Hospital, Vietnam, as an emerging medical tourism destination for cancer treatment across Asian countries. This accomplishment was presented by Professor Nguyen Thanh Liem at the NCRM NICHE 2025. He acknowledged the technology transfer support from GN Corporation, Japan, enabling the implementation of standardized AIET protocols in accordance with Japanese regulations, bringing treatment access to patients at Vinmec since 2018. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251026088789/en/ Professor Nguyen Thanh Liem, Director, Institute of Stem Cell and Genetic Technology Research at Vinmec International Hospital, Hanoi
METI will hold GGX Finance Summit27.10.2025 07:30:00 CET | Press release
On November 5 (Wed), the Ministry of Economy, Trade and Industry (METI) will hold the GGX Finance Summit at The Capitol Hotel Tokyu and on-line. In order to further develop discussions on transition finance, industry decarbonization, and other topics related to how business and finance contribute to decarbonization, we will promote mutual cooperation between the government, business, and financial sectors, and hold discussions to lead the international rule-making process to achieve both emission reductions and economic growth. Outline of GGX Finance Summit Date: November 5th, 2025 10:00-16:45 (JST, GMT+9:00) Venue: The Capitol Hotel Tokyu (Tokyo) (2-10-3, Nagata-cho, Chiyoda-ku, Tokyo 100-0014, Japan) Organizer: Ministry of Economy, Trade and Industry (METI), GX Acceleration Agency Co-organizer: World Business Council for Sustainable Development (WBCSD), TCFD Consortium Format: Hybrid (On-site and on-line) Language: Japanese/English (with English/Japanese simultaneous interpretation)
NITMX, Ant International and Krungthai Bank Expand Payment Connectivity Between Thailand and China via PromptPay27.10.2025 04:37:00 CET | Press release
The parties will promote inbound payments via PromptPay and Alipay, an Alipay+ e-wallet partner, enabling more convenience for Chinese travellersPartnership builds on Alipay+’s efforts to support the tourism industry in Thailand and enable local merchants to connect with travellers from China and beyond Under the guidance of the Bank of Thailand, Ant International, a leading global digital payment, digitisation and financial technology provider and National ITMX will partner to enhance and promote payments connectivity via PromptPay, between Thai merchants and Chinese consumers, which will be launched soon. Krungthai Bank will be the settlement bank for this cross-border QR partnership. In the initial phase, Chinese travellers to Thailand can use Alipay, an Alipay+ e-wallet partner, to make QR payment at millions of local merchants by scanning the PromptPay QR. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251026429360/en/
Helical Fusion Achieves Milestone Toward Commercial Fusion Energy, Advancing to Integrated Demonstration Device27.10.2025 04:00:00 CET | Press release
— World’s First Performance Test of a High-Temperature Superconducting Coil Under Conditions Replicating the Magnetic Environment Inside a Fusion Device — Helical Fusion Co., Ltd., a world-leading developer of the Helical Stellarator, has completed a critical performance test of a high-temperature superconducting (HTS) coil—a core component of commercial fusion reactors. The company has now commenced manufacturing and construction of its integrated demonstration device, Helix HARUKA. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251026597002/en/ Helical Fusion members celebrating the successful HTS test with an “HTS Graduation!” sign and graduation caps Watch the key points of this release in a 2-minute video: https://youtu.be/UhgQHfKtvow Helical Fusion is the only company in the world building upon expertise in the Helical Stellarator approach, accumulated for more than 60 years at national institutes and national universi
Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura® (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis26.10.2025 01:55:00 CEST | Press release
Eight-week results from the TRuE-AD4 trial demonstrate treatment with Opzelura® (ruxolitinib cream) significantly improved the clinical signs of atopic dermatitis (AD), including improved itch as early as Day 2, and was well tolerated in adults with moderate AD who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) At Week 8, 70% of patients treated with Opzelura achieved a ≥75% improvement in the Eczema Area and Severity Index (EASI75) and 61.3% achieved Investigator’s Global Assessment Treatment Success (IGA-TS), co-primary endpoints of the study Based on these results, Incyte expects to file a Type-II variation application for ruxolitinib cream 1.5% for the treatment of adults with moderate AD in the European Union (EU) by end of year Incyte (Nasdaq:INCY) today announced new data from the Phase 3b TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib cream) in adults with moder
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom